Cardiovascular Disease and Obesity Medications in Older Women by Obesity‐Related Cancers Status: SEER ‐Medicare 2007–2015
Obesity · 2026-06 · 34 (6) · 1343-1353
DOI: 10.1002/oby.70211 ↗At a glance
Journal article in Obesity, published online on 2026-05-04. Written by David S Lopez and 10 co-authors. Institution: Peter O'Donnell School of Public Health, UT Southwestern Medical Center, Dallas, Texas, USA. Major MEDLINE topics: Cardiovascular Diseases, Obesity, Neoplasms, Anti-Obesity Agents. 47 references. The full text is freely available (open access, CC BY 4.0). Funded by: NCI NIH HHS, Cancer Prevention and Research Institute of Texas, National Cancer Institute.
Abstract (original language)
Objective
This study evaluated the association between antiobesity medications (AOM) and incident cardiovascular disease (CVD) among older women, examining this relationship within and across survivors of obesity‐related cancers (ORCa) and age‐matched cancer‐free populations.
Methods
We conducted a retrospective cohort study using SEER–Medicare data from 2007 to 2015. The study included 46,552 women aged ≥ 65 years: ORCa survivors ( n = 23,276) and age‐ and index‐matched cancer‐free women ( n = 23,276). Prediagnostic AOM prescriptions before CVD onset were examined using intent‐to‐treat (ITT) and per‐protocol approaches. Multivariable Cox proportional hazards models estimated hazard ratios (HR) and 95% CI for incident CVD.
Results
In ITT analyses, AOM use was associated with lower CVD incidence in the composite analytic sample (HR = 0.80, 95% CI: 0.71–0.90) and among cancer‐free women (HR = 0.70, 95% CI: 0.58–0.85). Among ORCa survivors, estimates suggested a similar direction but were not statistically significant. In per‐protocol analyses, AOM use was associated with reduced CVD risk in ORCa survivors (HR = 0.74, 95% CI: 0.57–0.94) and cancer‐free women (HR = 0.59, 95% CI: 0.45–0.77). These associations were more pronounced within the first 2 years of follow‐up.
Conclusions
AOM use was inversely associated with incident CVD among ORCa survivors and cancer‐free women. Further studies of second‐generation AOM, particularly glucagon‐like peptide‐1 receptor agonists, are warranted.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Peter O'Donnell School of Public Health, UT Southwestern Medical Center, Dallas, Texas, USA.
- Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, USA.
- Department of Cardiovascular Medicine, University of Texas Medical Branch, Galveston, Texas, USA.
- Center for Population Health Research, National Institute of Public Health, Cuernavaca, Morelos, Mexico.
- Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA.
- Department of Internal Medicine, Division of Endocrinology, UT Southwestern Medical Center, Dallas, Texas, USA.
ORCID profiles: Jesús Gibran Hernández-Pérez, Maryam R Hussain, Mohanad Albayyaa, Jaime P Almandoz
Funding
- NCI NIH HHS
- Cancer Prevention and Research Institute of Texas
- National Cancer Institute
Cite
APA
Lopez, D. S., Abdelgadir, O., Zhang, Y., Hernández-Pérez, J. G., Hussain, M. R., Albayyaa, M., Nair, R., Kuo, Y. F., Almandoz, J. P., Cowell, L. G., & Messiah, S. E. (2026). Cardiovascular Disease and Obesity Medications in Older Women by Obesity‐Related Cancers Status: SEER ‐Medicare 2007–2015. Obesity, 34(6), 1343-1353. https://doi.org/10.1002/oby.70211
Vancouver
Lopez DS, Abdelgadir O, Zhang Y, Hernández-Pérez JG, Hussain MR, Albayyaa M, et al. Cardiovascular Disease and Obesity Medications in Older Women by Obesity‐Related Cancers Status: SEER ‐Medicare 2007–2015. Obesity. 2026;34(6):1343-1353. doi:10.1002/oby.70211
BibTeX
@article{Lopez2026,
author = {Lopez, David S and Abdelgadir, Omer and Zhang, Yuanyi and Hernández-Pérez, Jesús Gibran and Hussain, Maryam R and Albayyaa, Mohanad and Nair, Rasmi and Kuo, Yong-Fang and Almandoz, Jaime P and Cowell, Lindsay G and Messiah, Sarah E},
title = {Cardiovascular Disease and Obesity Medications in Older Women by Obesity‐Related Cancers Status: SEER ‐Medicare 2007–2015},
journal = {Obesity},
year = {2026},
volume = {34},
number = {6},
pages = {1343--1353},
doi = {10.1002/oby.70211}
}
EUVIMED